{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T17:58:20Z","timestamp":1795111100103,"version":"4.10.3"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genet"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1186\/s12881-019-0773-3","type":"journal-article","created":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T05:02:39Z","timestamp":1554786159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia"],"prefix":"10.1186","volume":"20","author":[{"given":"Diana Z.","family":"Osmanova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxim B.","family":"Freidin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga Yu.","family":"Fedorenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan V.","family":"Pozhidaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasiia S.","family":"Boiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia M.","family":"Vyalova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir V.","family":"Tiguntsev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena G.","family":"Kornetova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton J. M.","family":"Loonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arkadiy V.","family":"Semke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob","family":"Wilffert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolay A.","family":"Bokhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana A.","family":"Ivanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,9]]},"reference":[{"key":"773_CR1","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","volume":"374","author":"J Os van","year":"2009","unstructured":"van Os J, Kapur S. Schizophrenia. Lancet. 2009;374:635\u201345. https:\/\/doi.org\/10.1016\/S0140-6736(09)60995-8 .","journal-title":"Lancet."},{"key":"773_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.psym.2013.08.008","volume":"55","author":"A Ajmal","year":"2014","unstructured":"Ajmal A, Joffe H, Nachtigall LB. Psychotropic-induced hyperprolactinemia: a clinical review. Psychosomatics. 2014;55:29\u201336. https:\/\/doi.org\/10.1016\/j.psym.2013.08.008 .","journal-title":"Psychosomatics."},{"key":"773_CR3","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40263-014-0157-3","volume":"28","author":"J Peuskens","year":"2014","unstructured":"Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs. 2014;28:421\u201353. https:\/\/doi.org\/10.1007\/s40263-014-0157-3 .","journal-title":"CNS Drugs"},{"key":"773_CR4","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","volume":"64","author":"PM Haddad","year":"2004","unstructured":"Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinemia: mechanisms, clinical features, and management. Drugs. 2004;64:2291\u2013314 Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15456328 .","journal-title":"Drugs"},{"issue":"Pt 4","key":"773_CR5","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1258\/acb.2010.010025","volume":"47","author":"CJ Bushe","year":"2010","unstructured":"Bushe CJ, Bradley A, Pendlebury J. A review of hyperprolactinaemia and severe mental illness: are there implications for clinical biochemistry? Ann Clin Biochem. 2010;47(Pt 4):292\u2013300. https:\/\/doi.org\/10.1258\/acb.2010.010025 .","journal-title":"Ann Clin Biochem"},{"key":"773_CR6","doi-asserted-by":"publisher","first-page":"168","DOI":"10.4103\/0974-1208.121400","volume":"6","author":"A Majumdar","year":"2013","unstructured":"Majumdar A, Mangal NS. Hyperprolactinemia. J Hum Reprod Sci. 2013;6:168\u201375. https:\/\/doi.org\/10.4103\/0974-1208.121400 .","journal-title":"J Hum Reprod Sci"},{"key":"773_CR7","doi-asserted-by":"publisher","first-page":"T101","DOI":"10.1530\/JOE-15-0213","volume":"226","author":"DR Grattan","year":"2015","unstructured":"Grattan DR. 60 YEARS OF NEUROENDOCRINOLOGY: the hypothalamo-prolactin axis. J Endocrinol. 2015;226:T101\u201322. https:\/\/doi.org\/10.1530\/JOE-15-0213 .","journal-title":"J Endocrinol"},{"key":"773_CR8","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1210\/edrv-6-4-564","volume":"6","author":"N Ben-Jonathan","year":"1985","unstructured":"Ben-Jonathan N. Dopamine: a prolactin-inhibiting hormone. Endocr Rev. 1985;6:564\u201389. https:\/\/doi.org\/10.1210\/edrv-6-4-564 .","journal-title":"Endocr Rev"},{"key":"773_CR9","doi-asserted-by":"crossref","unstructured":"Caron MG, Beaulieu M, Raymond V, Gagn\u00e9 B, Drouin J, Lefkowitz RJ, Labrie F. Dopaminergic receptors in the anterior pituitary gland. Correlation of [3H]dihydroergocryptine binding with the dopaminergic control of prolactin release. J Biol Chem. 1978;253:2244\u201353 Available at: http:\/\/www.jbc.org\/content\/253\/7\/2244.long .","DOI":"10.1016\/S0021-9258(17)38065-1"},{"key":"773_CR10","doi-asserted-by":"publisher","first-page":"7625","DOI":"10.1073\/pnas.86.19.7625","volume":"86","author":"JH Meador-Woodruff","year":"1989","unstructured":"Meador-Woodruff JH, Mansour A, Bunzow JR, Van Tol HHM, Watson SJ, Civelli O. Distribution of D2 dopamine receptor mRNA in rat brain. Proc Natl Acad Sci U S A. 1989;86:7625\u20138 Available at: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC298119\/ .","journal-title":"Proc Natl Acad Sci U S A"},{"key":"773_CR11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1159\/000123140","volume":"32","author":"KT Demarest","year":"1981","unstructured":"Demarest KT, Mckay DW, Riegle GD, Moore KE. Sexual differences in tuberoinfundibular dopamine nerve activity induced by neonatal androgen exposure. Neuroendocrinology. 1981;32:108\u201313. https:\/\/doi.org\/10.1159\/000123140 .","journal-title":"Neuroendocrinology."},{"key":"773_CR12","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1210\/endo-106-2-526","volume":"106","author":"GA Gudelsky","year":"1980","unstructured":"Gudelsky GA, Porter JC. Release of dopamine from tuberoinfundibular neurons into pituitary stalk blood after prolactin or haloperidol administration. Endocrinology. 1980;106:526\u20139. https:\/\/doi.org\/10.1210\/endo-106-2-526 .","journal-title":"Endocrinology."},{"issue":"6","key":"773_CR13","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1176\/ajp.156.6.876","volume":"156","author":"P Seeman","year":"1999","unstructured":"Seeman P, Tallerico T. Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry. 1999;156(6):876\u201384. https:\/\/doi.org\/10.1176\/ajp.156.6.876 .","journal-title":"Am J Psychiatry"},{"issue":"3","key":"773_CR14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.euroneuro.2007.06.003","volume":"18","author":"K Linnet","year":"2008","unstructured":"Linnet K, Ejsing TB. A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs. Eur Neuropsychopharmacol. 2008;18(3):157\u201369. https:\/\/doi.org\/10.1016\/j.euroneuro.2007.06.003 .","journal-title":"Eur Neuropsychopharmacol"},{"key":"773_CR15","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.2217\/pgs.11.55","volume":"12","author":"T Moons","year":"2011","unstructured":"Moons T, de Roo M, Claes S, Dom G. Relationship between P-glycoprotein and second-generation antipsychotics. Pharmacogenomics. 2011;12:1193\u2013211. https:\/\/doi.org\/10.2217\/pgs.11.55 .","journal-title":"Pharmacogenomics."},{"issue":"7","key":"773_CR16","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/hup.720","volume":"20","author":"TB Ejsing","year":"2005","unstructured":"Ejsing TB, Pedersen AD, Linnet K. P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug-drug interaction experiments. Hum Psychopharmacol. 2005;20(7):493\u2013500. https:\/\/doi.org\/10.1002\/hup.720 .","journal-title":"Hum Psychopharmacol."},{"key":"773_CR17","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.brainres.2011.08.069","volume":"1420","author":"F Zhu","year":"2011","unstructured":"Zhu F, Yan CX, Wang Q, Zhu YS, Zhao Y, Huang J, et al. An association study between dopamine D1 receptor gene polymorphisms and the risk of schizophrenia. Brain Res. 2011;1420:106\u201313. https:\/\/doi.org\/10.1016\/j.brainres.2011.08.069 .","journal-title":"Brain Res"},{"issue":"6","key":"773_CR18","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/S1734-1140(09)70164-1","volume":"61","author":"K Grymek","year":"2009","unstructured":"Grymek K, \u0408ukasiewicz S, Faron-G\u0443reckaa A, Tworzydlo M, Polit A, Dziedzicka-Wasylewska M. Role of silent polymorphisms within the dopamine D1 receptor associated with schizophrenia on D1-D2 receptor heterodimerization. Pharmacol Rep. 2009;61(6):1024\u201333 Available at: http:\/\/www.if-pan.krakow.pl\/pjp\/pdf\/2009\/6_1024.pdf .","journal-title":"Pharmacol Rep"},{"issue":"1\u20133","key":"773_CR19","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.schres.2012.08.003","volume":"142","author":"VK Ota","year":"2012","unstructured":"Ota VK, Sp\u00edndola LN, Gadelha A, dos Santos Filho AF, Santoro ML, Christofolini DM, et al. DRD1 rs4532 polymorphism: a potential pharmacogenomic marker for treatment response to antipsychotic drugs. Schizophr Res. 2012;142(1\u20133):206\u20138. https:\/\/doi.org\/10.1016\/j.schres.2012.08.003 .","journal-title":"Schizophr Res"},{"issue":"1\u20132","key":"773_CR20","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.psychres.2015.07.054","volume":"229","author":"LP Matos De","year":"2015","unstructured":"De Matos LP, Santana CV, Souza RP. Meta-analysis of dopamine receptor D1 rs4532 polymorphism and susceptibility to antipsychotic treatment response. Psychiatry Res. 2015;229(1\u20132):586\u20138. https:\/\/doi.org\/10.1016\/j.psychres.2015.07.054 .","journal-title":"Psychiatry Res"},{"key":"773_CR21","doi-asserted-by":"publisher","first-page":"20552","DOI":"10.1073\/pnas.0707106104","volume":"104","author":"Y Zhang","year":"2007","unstructured":"Zhang Y, Bertolino A, Fazio L, Blasi G, Rampino A, Romano R, et al. Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proc Natl Acad Sci U S A. 2007;104:20552\u20137. https:\/\/doi.org\/10.1073\/pnas.0707106104 .","journal-title":"Proc Natl Acad Sci U S A"},{"key":"773_CR22","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/00008571-199712000-00006","volume":"7","author":"J Thompson","year":"1997","unstructured":"Thompson J, Thomas N, Singleton A, Piggott M, Lloyd S, Perry EK, et al. D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics. 1997;7:479\u201384 Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9429233 .","journal-title":"Pharmacogenetics"},{"key":"773_CR23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0920-9964(03)00220-2","volume":"67","author":"C Dubertret","year":"2004","unstructured":"Dubertret C, Gouya L, Hanoun N, Deybach JC, Ades J, Hamon M, Gorwood P. The 3\u2032 region of the DRD2 gene is involved in genetic susceptibility to schizophrenia. Schizophr Res. 2004;67:75\u201385. https:\/\/doi.org\/10.1016\/S0920-9964(03)00220-2 .","journal-title":"Schizophr Res"},{"issue":"11","key":"773_CR24","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.jpsychires.2007.10.007","volume":"42","author":"M Alenius","year":"2008","unstructured":"Alenius M, Wadelius M, Dahl ML, Hartvig P, Lindstrom L, Hammarlund-Udenaes M. Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting. J Psychiatr Res. 2008;42(11):884\u201393. https:\/\/doi.org\/10.1016\/j.jpsychires.2007.10.007 .","journal-title":"J Psychiatr Res"},{"issue":"4","key":"773_CR25","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1177\/0269881112463469","volume":"39","author":"BR Lawford","year":"2013","unstructured":"Lawford BR, Barnes M, Swagell CD, Connor JP, Burton SC, Heslop K, et al. DRD2\/ANKK1 Taq1A (rs1800497 C>T) genotypes are associated with susceptibility to second generation antipsychotic-induced akathisia. Schizophr Bull. 2013;39(4):848\u201356. https:\/\/doi.org\/10.1177\/0269881112463469 .","journal-title":"Schizophr Bull"},{"issue":"6","key":"773_CR26","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/j.1440-1819.2006.01594.x","volume":"60","author":"U Ettinger","year":"2006","unstructured":"Ettinger U, Joober RDE, Guzman R, O\u2019Driscoll GA. Schizotypy, attention deficit hyperactivity disorder, and dopamine genes. Psychiatry Clin Neurosci. 2006;60(6):764\u20137. https:\/\/doi.org\/10.1111\/j.1440-1819.2006.01594.x .","journal-title":"Psychiatry Clin Neurosci"},{"key":"773_CR27","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.biopsych.2006.04.012","volume":"60","author":"ME Talkowski","year":"2006","unstructured":"Talkowski ME, Mansour H, Chowdari KV, Wood J, Butler A, Varma PG, et al. Novel, replicated associations between dopamine D3 receptor gene polymorphisms and schizophrenia in two independent samples. Biol Psychiatry. 2006;60:570\u20137. https:\/\/doi.org\/10.1016\/j.biopsych.2006.04.012 .","journal-title":"Biol Psychiatry"},{"issue":"5","key":"773_CR28","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1093\/hmg\/ddm347","volume":"17","author":"ME Talkowski","year":"2008","unstructured":"Talkowski ME, Kirov G, Bamne M, Georgieva L, Torres G, Mansour H, et al. A network of dopaminergic gene variations implicated as risk factors for schizophrenia. Hum Mol Genet. 2008;17(5):747\u201358. https:\/\/doi.org\/10.1093\/hmg\/ddm347 .","journal-title":"Hum Mol Genet"},{"key":"773_CR29","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/ajmg.b.31203","volume":"156","author":"F Zhang","year":"2011","unstructured":"Zhang F, Fan H, Xu Y, Zhang K, Huang X, Zhu Y, et al. Converging evidence implicates the dopamine D3 receptor gene in vulnerability to schizophrenia. Am J Med Genet Part B. 2011;156:613\u20139. https:\/\/doi.org\/10.1002\/ajmg.b.31203 .","journal-title":"Am J Med Genet Part B"},{"issue":"6","key":"773_CR30","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/ajmg.b.30710","volume":"147B","author":"I Bombin","year":"2008","unstructured":"Bombin I, Arango C, Mayoral M, Castro-Fornieles J, Gonzalez-Pinto A, Gonzalez-Gomez C, et al. DRD3, but not COMT or DRD2, genotype affects executive functions in healthy and first-episode psychosis adolescents. Am J Med Genet Part B. 2008;147B(6):873\u20139. https:\/\/doi.org\/10.1002\/ajmg.b.30710 .","journal-title":"Am J Med Genet Part B."},{"issue":"3","key":"773_CR31","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.pnpbp.2009.01.010","volume":"33","author":"AF Hadithy Al","year":"2009","unstructured":"Al Hadithy AF, Ivanova SA, Pechlivanoglou P, Semke A, Fedorenko O, Kornetova E, et al. Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia. Prog Neuro-Psychopharmacol Biol Psychiatry. 2009;33(3):475\u201381. https:\/\/doi.org\/10.1016\/j.pnpbp.2009.01.010 .","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"6","key":"773_CR32","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.pnpbp.2010.05.017","volume":"34","author":"M Xu","year":"2010","unstructured":"Xu M, Xing Q, Li S, Zheng Y, Wu S, Gao R, et al. Pharmacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on extrapyramidal syndrome in schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry. 2010;34(6):1026\u201332. https:\/\/doi.org\/10.1016\/j.pnpbp.2010.05.017 .","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"2","key":"773_CR33","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.psychres.2014.05.039","volume":"219","author":"P Tybura","year":"2014","unstructured":"Tybura P, Trze\u015bniowska-Druka\u0142a B, Bienkowski P, Beszlej A, Frydecka D, Mierzejewski P, et al. Pharmacogenetics of adverse events in schizophrenia treatment: comparison study of ziprasidone, olanzapine and perazine. Psychiatry Res. 2014;219(2):261\u20137. https:\/\/doi.org\/10.1016\/j.psychres.2014.05.039 .","journal-title":"Psychiatry Res"},{"issue":"2","key":"773_CR34","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.pharmthera.2014.02.010","volume":"143","author":"JP Finberg","year":"2014","unstructured":"Finberg JP. Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release. Pharmacol Ther. 2014;143(2):133\u201352. https:\/\/doi.org\/10.1016\/j.pharmthera.2014.02.010 .","journal-title":"Pharmacol Ther"},{"key":"773_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0165-1781(00)00162-1","volume":"95","author":"SB Manuck","year":"2000","unstructured":"Manuck SB, Flory JD, Ferrell RE, Mann JJ, Muldoon MF. A regulatory polymorphism of the monoamine oxidase a gene may be associated with variability in aggression, impulsivity, and central nervous system serotonergic responsivity. Psychiatry Res. 2000;95:9\u201323. https:\/\/doi.org\/10.1016\/S0165-1781(00)00162-1 .","journal-title":"Psychiatry Res"},{"issue":"5","key":"773_CR36","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1097\/JCP.0b013e31829abec9","volume":"33","author":"M Zivkovi\u0107","year":"2013","unstructured":"Zivkovi\u0107 M, Mihaljevi\u0107-Peles A, Bozina N, Sagud M, Nikolac-Perkovic M, Vuksan-Cusa B, et al. The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol. J Clin Psychopharmacol. 2013;33(5):593\u20139. https:\/\/doi.org\/10.1097\/JCP.0b013e31829abec9 .","journal-title":"J Clin Psychopharmacol"},{"key":"773_CR37","unstructured":"Terzi\u0107 T, Kastelic M, Dol\u017ean V, Plesni\u010dar BK. Genetic polymorphisms in dopaminergic system and treatment-resistant schizophrenia. Psychiatr Danub. 2016;28(2):127\u201331 Available at: http:\/\/www.psychiatria-danubina.com\/UserDocsImages\/pdf\/dnb_vol28_no2\/dnb_vol28_no2_127.pdf ."},{"key":"773_CR38","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.2147\/NDT.S148824","volume":"13","author":"J Han","year":"2017","unstructured":"Han J, Li Y, Wang X. Potential link between genetic polymorphisms of catechol-O-methyltransferase and dopamine receptors and treatment efficacy of risperidone on schizophrenia. Neuropsychiatr Dis Treat. 2017;13:2935\u201343. https:\/\/doi.org\/10.2147\/NDT.S148824 eCollection 2017.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"773_CR39","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.schres.2016.10.029","volume":"182","author":"SA Ivanova","year":"2017","unstructured":"Ivanova SA, Osmanova DZ, Boiko AS, Pozhidaev IV, Freidin MB, Fedorenko OY, et al. Prolactin gene polymorphism (-1149 G\/T) is associated with hyperprolactinemia in patients with schizophrenia treated with antipsychotics. Schizophr Res. 2017;182:110\u20134. https:\/\/doi.org\/10.1016\/j.schres.2016.10.029 .","journal-title":"Schizophr Res"},{"issue":"3","key":"773_CR40","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/15622975.2016.1224926","volume":"18","author":"SA Ivanova","year":"2017","unstructured":"Ivanova SA, Osmanova DZ, Freidin MB, Fedorenko OY, Boiko AS, Pozhidaev IV, et al. Identification of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia. World J Biol Psychiatry. 2017;18(3):239\u201346. https:\/\/doi.org\/10.1080\/15622975.2016.1224926 .","journal-title":"World J Biol Psychiatry"},{"issue":"3","key":"773_CR41","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.biopsych.2009.08.040","volume":"67","author":"NC Andreasen","year":"2010","unstructured":"Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry. 2010;67(3):255\u201362. https:\/\/doi.org\/10.1016\/j.biopsych.2009.08.040 .","journal-title":"Biol Psychiatry"},{"key":"773_CR42","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/1471-244X-13-214","volume":"13","author":"DL Kelly","year":"2013","unstructured":"Kelly DL, Wehring HJ, Earl AK, Sullivan KM, Dickerson FB, Feldman S, et al. Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (dopamine partial agonist, aripiprazole, for the Management of Symptomatic ELevated prolactin). BMC Psychiatry. 2013;13:214. https:\/\/doi.org\/10.1186\/1471-244X-13-214 .","journal-title":"BMC Psychiatry"},{"key":"773_CR43","unstructured":"Gonzalez JR, Armengol L, Guino E, Sole X, Moreno V. SNPassoc: SNPs-based whole genome association studies. R package version 1.9\u20132. 2014, Available at: https:\/\/CRAN.R-project.org\/package=SNPassoc"},{"key":"773_CR44","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1210\/jcem.83.3.4675","volume":"83","author":"L Katznelson","year":"1998","unstructured":"Katznelson L, Riskind PN, Saxe VC, Klibanski A. Prolactin pulsatile characteristics in postmenopausal women. J Clin Endocrinol Metab. 1998;83:761\u20134. https:\/\/doi.org\/10.1210\/jcem.83.3.4675 .","journal-title":"J Clin Endocrinol Metab"},{"key":"773_CR45","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1530\/acta.0.1250621","volume":"125","author":"PR Maddox","year":"1991","unstructured":"Maddox PR, Jones DL, Mansel RE. Basal prolactin and total lactogenic hormone levels by microbioassay and immunoassay in normal human sera. Acta Endocrinol (Copenh). 1991;125:621\u20137 Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/1789057 .","journal-title":"Acta Endocrinol (Copenh)"},{"key":"773_CR46","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1479-828X.2011.01321.x","volume":"51","author":"MJ Tanner","year":"2011","unstructured":"Tanner MJ, Hadlow NC, Wardrop R. Variation of female prolactin levels with menopausal status and phase of menstrual cycle. Aust NZJ Obstet Gynaecol. 2011;51:321\u20134. https:\/\/doi.org\/10.1111\/j.1479-828X.2011.01321.x .","journal-title":"Aust NZJ Obstet Gynaecol"},{"issue":"5","key":"773_CR47","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1523\/JNEUROSCI.12-05-01977.1992","volume":"12","author":"J Saura","year":"1992","unstructured":"Saura J, Kettler R, Da Prada M, Richards JG. Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. J Neurosci. 1992;12(5):1977\u201399. https:\/\/doi.org\/10.1523\/JNEUROSCI.12-05-01977.1992 .","journal-title":"J Neurosci"},{"issue":"3","key":"773_CR48","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S0306-4522(96)83013-2","volume":"70","author":"J Saura","year":"1996","unstructured":"Saura J, Bleuel Z, Ulrich J, Mendelowitsch A, Chen K, Shih JC, et al. Molecular neuroanatomy of human monoamine oxidases a and B revealed by quantitative enzyme radioautography and in situ hybridization histochemistry. Neuroscience. 1996;70(3):755\u201374. https:\/\/doi.org\/10.1016\/S0306-4522(96)83013-2 .","journal-title":"Neuroscience."},{"key":"773_CR49","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/ana.410330406","volume":"33","author":"JH Kurth","year":"1993","unstructured":"Kurth JH, Kurth MC, Poduslo SE, Schwankhaus JD. Association of a monoamine oxidase B allele with Parkinson's disease. Ann Neurol. 1993;33:368\u201372. https:\/\/doi.org\/10.1002\/ana.410330406 .","journal-title":"Ann Neurol"},{"key":"773_CR50","doi-asserted-by":"publisher","unstructured":"Liu JJ, Wang W, Meng M, Liang CS, Zhang JW. Association between monoamine oxidase B A644G polymorphism and Parkinson's disease risk: a meta-analysis in the Chinese population. Genet Mol Res. 2016;15(2). https:\/\/doi.org\/10.4238\/gmr.15028349 .","DOI":"10.4238\/gmr.15028349"},{"key":"773_CR51","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1744-9081-7-42","volume":"7","author":"W Yi-Liang","year":"2011","unstructured":"Yi-Liang W, Li C-X, Li S-B, Liu Y, Lan H. Association study of monoamine oxidase A\/B genes and schizophrenia in Han Chinese. Behav Brain Funct. 2011;7:42. https:\/\/doi.org\/10.1186\/1744-9081-7-42 .","journal-title":"Behav Brain Funct"},{"key":"773_CR52","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s00702-009-0281-2","volume":"116","author":"AM Dlugos","year":"2009","unstructured":"Dlugos AM, Palmer AA, de Wit H. Negative emotionality: monoamine oxidase B gene variants modulate personality traits in healthy humans. J Neural Transm. 2009;116:1323\u201334. https:\/\/doi.org\/10.1007\/s00702-009-0281-2 .","journal-title":"J Neural Transm"},{"key":"773_CR53","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000159774","volume":"58","author":"P Gasso","year":"2008","unstructured":"Gasso P, Bernardo M, Mas S, Crescenti A, Garcia C, Parellada E, et al. Association of a\/G polymorphism in intron 13 of the monoamine oxidase B gene with schizophrenia in a Spanish population. Neuropsychobiology. 2008;58:65\u201370. https:\/\/doi.org\/10.1159\/000159774 .","journal-title":"Neuropsychobiology."},{"issue":"5","key":"773_CR54","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/hup.1130","volume":"25","author":"SG Kang","year":"2010","unstructured":"Kang SG, Park YM, Choi JE, Lim SW, Lee HJ, Lee SH, et al. Association study between antipsychotic-induced restless legs syndrome and polymorphisms of monoamine oxidase genes in schizophrenia. Hum Psychopharmacol. 2010;25(5):397\u2013403. https:\/\/doi.org\/10.1002\/hup.1130 .","journal-title":"Hum Psychopharmacol"},{"key":"773_CR55","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/j.1529-8817.2005.00228.x","volume":"70","author":"AC Need","year":"2006","unstructured":"Need AC, Ahmadi KR, Spector TD, Goldstein DB. Obesity is associated with genetic variants that Alter dopamine availability. Ann Hum Genet. 2006;70:293\u2013303. https:\/\/doi.org\/10.1111\/j.1529-8817.2005.00228.x .","journal-title":"Ann Hum Genet"},{"issue":"2","key":"773_CR56","first-page":"71","volume":"32","author":"T Mitsuma","year":"1998","unstructured":"Mitsuma T, Rhue H, Hirooka Y, Kayama M, Wago T, Takagi J, et al. Distribution of dopamine transporter in the rat: an Immunohistochemical study. Endocr Regul. 1998;32(2):71\u20135 Available at: https:\/\/www.sav.sk\/journals\/endo\/full\/er0298b.pdf .","journal-title":"Endocr Regul"},{"issue":"1","key":"773_CR57","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1210\/endo.141.1.7281","volume":"141","author":"JE Demaria","year":"2000","unstructured":"Demaria JE, Nagy GM, Lerant AA, Fekete MI, Levenson CW, Freeman ME. Dopamine transporters participate in the physiological regulation of prolactin. Endocrinology. 2000;141(1):366\u201374. https:\/\/doi.org\/10.1210\/endo.141.1.7281 .","journal-title":"Endocrinology."},{"key":"773_CR58","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0924-977X(01)00122-5","volume":"11","author":"MJ Bannon","year":"2001","unstructured":"Bannon MJ, Michelhaugh SK, Wang J, Sacchetti P. The human dopamine transporter gene: gene organization, transcriptional regulation, and potential involvement in neuropsychiatric disorders. Eur Neuropsychopharmacol. 2001;11:449\u201355. https:\/\/doi.org\/10.1016\/S0924-977X(01)00122-5 .","journal-title":"Eur Neuropsychopharmacol"},{"key":"773_CR59","doi-asserted-by":"publisher","first-page":"E847","DOI":"10.1208\/aapsj070481","volume":"7","author":"EL Riddle","year":"2005","unstructured":"Riddle EL, Fleckenstein AE, Hanson GR. Role of monoamine transporters in mediating psychostimulant effects. AAPS J. 2005;7:E847\u201351. https:\/\/doi.org\/10.1208\/aapsj070481 .","journal-title":"AAPS J"},{"key":"773_CR60","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2174\/187152706784111579","volume":"5","author":"TD Sotnikova","year":"2006","unstructured":"Sotnikova TD, Beaulieu JM, Gainetdinov RR, Caron MG. Molecular biology, pharmacology and functional role of the plasma membrane dopamine transporter. CNS Neurol Disord Drug Targets. 2006;5:45\u201356. https:\/\/doi.org\/10.2174\/187152706784111579 .","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"773_CR61","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00213-003-1700-y","volume":"173","author":"H Sjoholm","year":"2004","unstructured":"Sjoholm H, Bratlid T, Sundsfjord J. 123I-beta-CIT SPECT demonstrates increased presynaptic dopamine transporter binding sites in basal ganglia in vivo in schizophrenia. Psychopharmacology (Berl). 2004;173:27\u201331. https:\/\/doi.org\/10.1007\/s00213-003-1700-y .","journal-title":"Psychopharmacology (Berl)"},{"issue":"7","key":"773_CR62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0102556","volume":"9","author":"H Kaur","year":"2014","unstructured":"Kaur H, Jajodia A, Grover S, Baghel R, Gupta M, Jain S, et al. Genetic variations of PIP4K2A confer vulnerability to poor antipsychotic response in severely ill schizophrenia patients. PLoS One. 2014;9(7):e102556. https:\/\/doi.org\/10.1371\/journal.pone.0102556 eCollection 2014.","journal-title":"PLoS One"}],"container-title":["BMC Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12881-019-0773-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12881-019-0773-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12881-019-0773-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T14:36:08Z","timestamp":1663252568000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenet.biomedcentral.com\/articles\/10.1186\/s12881-019-0773-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":62,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["773"],"URL":"https:\/\/doi.org\/10.1186\/s12881-019-0773-3","relation":{},"ISSN":["1471-2350"],"issn-type":[{"value":"1471-2350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"9 April 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This work was performed in accordance with The Code of Ethics of the World Medical Association for experiments involving humans (Declaration of Helsinki 1975, revised in Fortaleza, Brazil, 2013). All participants gave their signed informed consent to participate, and the study was approved by the Local Bioethics Committee of the Mental Health Research Institute (protocol N63\/7.2014).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"47"}}